HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
ViiV Healthcare
ClinicalTrials.gov Identifier:
NCT00450580
First received: March 21, 2007
Last updated: May 31, 2012
Last verified: April 2012
  Purpose

This is a Phase IIIB, 48 Week, multicentre, randomized, open-label, parallel group study comparing the safety and efficacy of fosamprenavir plus ritonavir 1400mg/100mg once-daily to fosamprenavir plus ritonavir 700mg/100mg twice-daily, both administered with abacavir/lamivudine 600mg/300mg once-daily in antiretroviral-naive HIV-1 infected adults. This study utilizes a group-sequential design with two stages: 1) an interim 24 week cohort analysis of approximately 200 subjects and 2) if study continuation criteria are met at this interim analysis, further enrolment of an additional 528 subjects, followed over a minimum of 48 weeks. The objectives of the study are to demonstrate 1) non-inferior antiviral activity of fosamprenavir/ritonavir 1400mg/100mg QD compared to fosamprenavir/ritonavir 700mg/100mg BID and 2) a superior fasting non-HDL lipid profile in subjects receiving fosamprenavir/ritonavir 1400mg/100mg QD.


Condition Intervention Phase
Infection, Human Immunodeficiency Virus I
HIV-1 Infection
Drug: fosamprenavir/ritonavir
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Study of Once-Daily Versus Twice-Daily Fosamprenavir Plus Ritonavir, Administered With Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Adult Subjects.

Resource links provided by NLM:


Further study details as provided by ViiV Healthcare:

Primary Outcome Measures:
  • Percentage of Participants With HIV-1 RNA <400 and >=400 Copies/mL Over 48 Weeks [ Time Frame: Week 48 ] [ Designated as safety issue: No ]
    A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies/mL at week 48. The percentage of participants with HIV-1 RNA <400 copies/mL at Week 48 was determined by the Time to Loss Of Virologic Response (TLOVR) algorithm.


Secondary Outcome Measures:
  • Percentage of Participants With HIV-1 RNA <50 and >=50 Copies/mL by Visit Over 48 Weeks [ Time Frame: Week 48 ] [ Designated as safety issue: No ]
    A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies/mL at week 48. The percentage of participants with HIV-1 RNA <50 copies/mL at Week 48 was determined by the TLOVR algorithm

  • Number of Participants With HIV-1 RNA <400 Copies/mL (Primary Endpoint) at Week 48 Categorised by Baseline Viral Load, TLOVR Analysis [ Time Frame: Week 48 ] [ Designated as safety issue: No ]
    The number of participants with HIV-1 RNA <400 copies/mL at Week 48 was determined (by analysis of blood draw) and categorised by baseline viral load (BVL).

  • Number of Participants With HIV-1 RNA <400 Copies/mL (Primary Endpoint) at Week 48 Categorised by Baseline CD4+ Count, TLOVR Analysis [ Time Frame: Week 48 ] [ Designated as safety issue: No ]
    The number of participants with HIV-1 RNA <400 copies/mL at week 48 was determined (by analysis of blood draw) and categorised by baseline CD4+ count.

  • Change From Baseline in Non-HDL Cholesterol at Week 48 [ Time Frame: Week 48 ] [ Designated as safety issue: Yes ]
    Blood samples were drawn to determine the non-HDL cholesterol levels at Week 48. The mean absolute change in non-HDL cholesterol was defined as the Week 48 levels minus levels at baseline.

  • Number of Protocol-defined Virological Failures With Genotypic and Phenotypic Resistance Changes [ Time Frame: Time to virologic failure; Week 4 up to Week 48 ] [ Designated as safety issue: No ]
    A blood sample was drawn at the time of confirmation of virological failure, and mutations present in the virus were identified and compared to those found in the blood sample at baseline. New mutations were tabulated by drug class. RT, reverse transcriptase. Virological failure could occur anytime from Week 4 to Week 48.

  • Steady-state Levels of Amprenavir (APV) and Ritonavir (RTV) Ctau at Weeks 4, 12, and 24 [ Time Frame: Weeks 4, 12, and 24 ] [ Designated as safety issue: No ]
    Blood samples were drawn at Weeks 4, 12, and 24 to determine plasma concentrations (Ctau) of APV and RTV

  • Study Endpoints for a Subset of Subjects Receiving Study Drug Beyond 48 Weeks [ Time Frame: Up to 60 weeks ] [ Designated as safety issue: No ]
    Adaptive two-stage design study up to 48 weeks. N=200, expanding to 728 if continuation criteria were achieved based on a 24-week interim analysis. The initial 200 participants would continue until the last subject of the expanded cohort reached 48 weeks and would constitute the subset. As continuation criteria were not achieved, the study did not proceed to the second stage, and full analysis was performed on the initial 200 participants only.


Enrollment: 212
Study Start Date: March 2007
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A
Fosamprenavir/ritonavir 1400mg/100mg QD + ABC/3TC FDC 600/300mg QD
Drug: fosamprenavir/ritonavir
Fosamprenavir (FPV, TELZIR) is currently licensed in Europe for twice daily (BID) dosing in combination with ritonavir (RTV, Norvir) as a boosting agent
Other Name: fosamprenavir/ritonavir
Active Comparator: Arm B
Fosamprenavir/ritonavir 700mg/100mg BID + ABC/3TC FDC 600/300mg QD
Drug: fosamprenavir/ritonavir
Fosamprenavir (FPV, TELZIR) is currently licensed in Europe for twice daily (BID) dosing in combination with ritonavir (RTV, Norvir) as a boosting agent
Other Name: fosamprenavir/ritonavir

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject is ≥18 years of age.
  • Subject is antiretroviral-naïve (defined as having ≤14 days of prior therapy with any antiretroviral agent).
  • Subject has plasma HIV-1 RNA ≥1,000 copies/mL at screening.
  • Subject is willing and able to understand and provide written informed consent prior to participation in this study.
  • A female is eligible to enter and participate in the study if she is of:

    1. Non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal); or,
    2. Child-bearing potential, has a negative pregnancy test (serum b-HCG) at screen and agrees to one of the following methods of contraception (any contraception method must be used consistently and correctly, i.e., in accordance with both the approved product label and the instructions of a physician):

      • Complete abstinence from intercourse from 2 weeks prior to administration of the investigational products, throughout the study, and for at least 2 weeks after discontinuation of all study medications
      • Double barrier method (male condom/spermicide, male condom/diaphragm, diaphragm/spermicide). Hormonal contraception will not be permitted in this study
      • Any intrauterine device (IUD) with published data showing that the expected failure rate is <1% per year.
      • Sterilization (female subject or male partner of female subject). All subjects participating in the study should be counselled on the practice of safer sex.
  • Prior to randomization, subjects entering Stage 2 must have been screened and be negative for the HLA-B*5701 allele. Test may be performed by local laboratory and results must be available for source document verification according to local practices.

Exclusion Criteria:

  • Subject is in the initial acute phase of a CDC Clinical Category C infection at Baseline. Subjects may be enrolled provided they are receiving treatment for such infections and are clinically improving at the Baseline visit.
  • Subject is enrolled in one or more investigational drug protocols, which may impact HIV RNA suppression.
  • Subject is, in the opinion of the Investigator, unable to complete the study dosing period and protocol evaluations and assessments.
  • Subject is either pregnant or breastfeeding.
  • Subject suffers from any serious medical condition (such as pancreatitis, diabetes, congestive heart failure, cardiomyopathy or other cardiac dysfunction) which in the opinion of the Investigator would compromise the safety of the subject.
  • Subject has a pre-existing mental, physical, or substance abuse disorder which, in the opinion of the Investigator, may interfere with the subject's ability to comply with the dosing schedule and protocol evaluations and assessments.
  • Subject has a history of inflammatory bowel disease or intestinal malignancy, intestinal ischemia, malabsorption, or other gastrointestinal dysfunction, which, in the opinion of the Investigator, may interfere with drug absorption or render the subject unable to take oral medication.
  • Subject has any acute laboratory abnormality at screening, which, in the opinion of the Investigator, would preclude the subject's participation in the study of an investigational compound. If subjects are found to have an acute Grade 4 laboratory abnormality at screening, this test may be repeated once within the 45-day screening window. Any verified Grade 4 laboratory abnormality would exclude a subject from study participation.
  • Subject has an estimated creatinine clearance < 50 mL/min via the Cockcroft-Gault method [Cockcroft, 1976]. This test may be repeated once within the 45-day screening window.

NOTE: Creatinine clearance should be estimated using the following formula:

For serum creatinine concentration in mg/dL:

For serum creatinine concentration in µmol/L:

  • Alanine aminotransferase (ALT) >5 times the upper limit of normal (ULN) or hepatic impairment as determined by Child-Pugh Score ≥ 5.
  • Subject is receiving, or has received within 90 days prior to screen, any lipid lowering agent, including drugs from the following classes: HMG-CoA reductase inhibitors (statins), niacin, fibrates, bile acid sequestrants, and/or fish oil supplements. Subjects anticipated to require initiation of therapy with these agents within 12 weeks of Baseline are not eligible to participate.
  • Subject has received treatment with radiation therapy or cytotoxic chemotherapeutic agents within 28 days prior to Screening, or has an anticipated need for these agents within the study period.
  • Subject has received treatment with an HIV-1 immunotherapeutic vaccine or any agents with documented activity against HIV-1 in vitro within 28 days prior Screening, or an anticipated need during the study.
  • Subjects who require treatment with any of the following medications within 28 days of commencement of investigational product, or an anticipated need during the study:

    • Amiodarone, astemizole, bepridil, cisapride, dihydroergotamine, ergonovine, ergotamine, flecainide, halofantrine, lidocaine, lovastatin, methylergonovine, midazolam, pimozide, propafenone, quinidine, simvastatin, terfenadine, triazolam.
    • Carbamazepine, dexamethasone, phenobarbital, phenytoin, primidone, rifampin, St Johns Wort (Hypericum perforatum), troglitazone.
    • Systemic interleukins or interferons.
  • Subject has a history of allergy to any of the investigational products or any excipients therein.
  • Subject has evidence of genotypic (as defined by the current ANRS AC-11 algorithm) resistance at screening or prior documented evidence of genotypic and/or phenotypic (above threshold for reduced susceptibility) resistance to amprenavir/ritonavir, abacavir or lamivudine.
  • Subjects recruited at sites in France will be excluded if:

    • The subject is not affiliated with or a beneficiary of a social security.
    • The subject has previously participated in an experimental drug and/or vaccine trial(s) within 60 days or 5 half-lives, or twice the duration of the biological effect of the experimental drug or vaccine - whichever is longer, prior to screening for the study.
    • The subject will participate simultaneously in another clinical study. Notwithstanding these minimum inclusion and exclusion criteria, investigators are urged to follow country specific guidelines where they exist when making decisions about subjects who are eligible for study participation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00450580

  Hide Study Locations
Locations
Belgium
GSK Investigational Site
Antwerpen, Belgium, 2000
GSK Investigational Site
Brussel, Belgium, 1090
GSK Investigational Site
Gent, Belgium, 9000
France
GSK Investigational Site
Besançon, France, 25030
GSK Investigational Site
Bordeaux, France, 33000
GSK Investigational Site
Clamart, France, 92140
GSK Investigational Site
La Roche Sur Yon cedex 9, France, 85025
GSK Investigational Site
Levallois-Perret, France, 92300
GSK Investigational Site
Lyon Cedex 03, France, 69437
GSK Investigational Site
Nantes, France, 44093
GSK Investigational Site
Nice, France, 06202
GSK Investigational Site
Orléans, France, 45100
GSK Investigational Site
Paris, France, 75018
GSK Investigational Site
Paris, France, 75010
GSK Investigational Site
Paris Cedex 10, France, 75475
GSK Investigational Site
Paris Cedex 13, France, 75651
GSK Investigational Site
Saint Denis Cedex 01, France, 93205
GSK Investigational Site
Strasbourg, France, 67000
GSK Investigational Site
Suresnes Cedex, France, 92151
GSK Investigational Site
Tourcoing, France, 59208
Germany
GSK Investigational Site
Freiburg, Baden-Wuerttemberg, Germany, 79106
GSK Investigational Site
Freiburg, Baden-Wuerttemberg, Germany, 79098
GSK Investigational Site
Stuttgart, Baden-Wuerttemberg, Germany, 70197
GSK Investigational Site
Fuerth, Bayern, Germany, 90762
GSK Investigational Site
Muenchen, Bayern, Germany, 80801
GSK Investigational Site
Frankfurt, Hessen, Germany, 60596
GSK Investigational Site
Frankfurt, Hessen, Germany, 60590
GSK Investigational Site
Frankfurt, Hessen, Germany, 60311
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30625
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30159
GSK Investigational Site
Osnabrueck, Niedersachsen, Germany, 49090
GSK Investigational Site
Dortmund, Nordrhein-Westfalen, Germany, 44137
GSK Investigational Site
Koeln, Nordrhein-Westfalen, Germany, 50937
GSK Investigational Site
Hamburg, Germany, 20246
GSK Investigational Site
Hamburg, Germany, 20146
Italy
GSK Investigational Site
Catanzaro, Calabria, Italy, 88100
GSK Investigational Site
Roma, Lazio, Italy, 00185
GSK Investigational Site
Roma, Lazio, Italy, 00161
GSK Investigational Site
Brescia, Lombardia, Italy, 25125
GSK Investigational Site
Busto Arsizio (VA), Lombardia, Italy, 21052
GSK Investigational Site
Milano, Lombardia, Italy, 20142
GSK Investigational Site
Milano, Lombardia, Italy, 20127
GSK Investigational Site
Grosseto, Toscana, Italy, 58100
Romania
GSK Investigational Site
Bucharest, Romania, 030303
GSK Investigational Site
Bucharest, Romania, 021105
GSK Investigational Site
Constanta, Romania, 900709
GSK Investigational Site
Iasi, Romania, 700116
Russian Federation
GSK Investigational Site
St. Petersburg, Russian Federation, 196645
GSK Investigational Site
Volgograd, Russian Federation, 400040
Spain
GSK Investigational Site
Barcelona, Spain, 08025
GSK Investigational Site
Barcelona, Spain, 08036
GSK Investigational Site
Barcelona, Spain, 8400
GSK Investigational Site
Barcelona, Spain, 08907
GSK Investigational Site
Elche (Alicante), Spain, 03202
GSK Investigational Site
La Coruña, Spain, 15006
GSK Investigational Site
Madrid, Spain, 28041
GSK Investigational Site
Madrid, Spain, 28040
GSK Investigational Site
Madrid, Spain, 28046
GSK Investigational Site
Madrid, Spain, 28029
GSK Investigational Site
Malaga, Spain, 29010
GSK Investigational Site
Marid, Spain, 28040
GSK Investigational Site
Mataro, Spain, 08034
GSK Investigational Site
Santiago de Compostela, Spain, 15706
GSK Investigational Site
Sevilla, Spain, 41013
GSK Investigational Site
Valencia, Spain, 46015
Switzerland
GSK Investigational Site
St Gallen, Switzerland, 9007
United Kingdom
GSK Investigational Site
London, United Kingdom, SW10 9TH
GSK Investigational Site
London, United Kingdom, NW3 2QG
GSK Investigational Site
London, United Kingdom, SE1 7EH
Sponsors and Collaborators
ViiV Healthcare
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials ViiV Healthcare
  More Information

Publications:
Carosi G, Lazzarin A, Stellbrink H, et al. Efficacy and Safety of Fosamprenavir + Ritonavir (FPV/RTV) 700mg/100mg Twice Daily (BID) Versus FPV/RTV 1400mg/100mg Once Daily (QD) with ABC/3TC QD over 24 Weeks. Abstract H-1244, 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2008.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: ViiV Healthcare
ClinicalTrials.gov Identifier: NCT00450580     History of Changes
Other Study ID Numbers: APV109141
Study First Received: March 21, 2007
Results First Received: July 24, 2009
Last Updated: May 31, 2012
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
Belgium: Federal Agency for Medicinal Products and Health Products
Spain: Ministry of Health and Consumption
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Romania: National Medicines Agency
Italy: The Italian Medicines Agency

Keywords provided by ViiV Healthcare:
protease inhibitor,
HIV-1,
Fosamprenavir,
non-HDL cholesterol
ritonavir,
naive,

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Immune System Diseases
Protease Inhibitors
Ritonavir
Fosamprenavir
HIV Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on August 01, 2014